Submission of Transcript of Earnings Call
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
MedPlus reported Q4 FY26 consolidated revenue of INR 18,644 million with operating EBITDA of INR 1,076 million (5.8% margin). The company added 218 net stores in Q4, taking total network to 5,330 stores. For FY27, management guided 800 net new store additions including franchisee outlets. Private label sales currently constitute 22% of total revenue. The company clarified it has zero external debt (previous interest expenses were related to lease accounting under Ind AS). Management declined to provide margin guidance but stated intention to first stabilize current profitability levels before expanding. On the franchisee model, MedPlus retains 9.5-10% store-level EBITDA per franchisee outlet. The company also mentioned plans to upgrade 600+ stores to accommodate more private label non-pharma assortment.
The earnings call shows steady operational execution with store expansion on track and margins holding steady. However, management's refusal to give explicit margin improvement guidance despite strong Q4 numbers may limit near-term upside expectations for investors looking for growth signals.